The Corporate Reputation of Pharma, 2017: The Patient Perspective - Asia Edition - ResearchAndMarkets.com

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nov 13, 2018 11:28 am
DUBLIN -- 

The "The Corporate Reputation of Pharma, 2017 - The Patient Perspective - Asia Edition" report has been added to ResearchAndMarkets.com's offering.

Introducing the results of the 2017 (2nd) edition of The Corporate Reputation of Pharma - from the Perspective of Asian Patient Groups. In total, 101 Asian patient groups from across the region participated in the 2017 survey (with 35% of the respondents being based in Australasia).

Asian patient groups (and the patients they represent), on the whole, take a more positive view of the pharmaceutical industry than patient groups from elsewhere in the world. As many as 51% of the respondent Asian patient groups stated that the pharmaceutical industry as a whole had an Excellent or Good corporate reputation in 2017 (on a par with the 50% of Asian patient groups saying the same in 2016). The equivalent figure from patient groups worldwide in 2017 was 43%.

Companies Featured

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Boehringer,ngelheim
  • Bristol-Myers Squibb
  • Eisai
  • Eli Lilly (Lilly)
  • GSK
  • Gilead Sciences
  • Janssen
  • Merck & Co/MSD
  • Novartis
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Takeda

Key Topics Covered

  1. Executive Summary
  2. The Relationships that Asian Patient Groups have with Pharma, 2017
  3. Industry-Wide Findings from Asian Patient Groups, 2017
  4. Rankings of the 18 Pharma Companies, 2017 v. 2016 among Asian Patient Groups Familiar with the Companies
  5. Positionings of 11 Pharma Companies, 2017 v. 2016 among Asian Patient Groups that Work/Partner with the Companies
  6. Profiles of the 18 Companies, 2017

For more information about this report visit https://www.researchandmarkets.com/research/n3th2c/the_corporate?w=4

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).